J.B. Chemicals & Pharmaceuticals announced an 8% increase in revenue, reaching INR 1085 crores in Q2 FY26. Operating EBITDA rose by 12% to INR 319 crores, while Net Profit increased by 19% to INR 208 crores. The company’s domestic business continues to outperform the market, driving robust growth. They are focused on building a progressive, agile, and future-ready organization.
Q2 FY26 Financial Highlights
J.B. Chemicals & Pharmaceuticals Ltd announced its financial results for the quarter ended September 30, 2025, showcasing strong growth across key metrics:
- Revenue: INR 1,085 crores, up 8% from INR 1,001 crores in Q2 FY25.
- Operating EBITDA: INR 319 crores, a 12% increase compared to INR 285 crores in the same quarter last year.
- Net Profit: INR 208 crores, reflecting a 19% rise from INR 175 crores in Q2 FY25.
Operating EBITDA is after excluding non-cash ESOP charge and one off charges.
H1 FY26 Performance Overview
For the first half of FY26, the company reported:
- Revenue: INR 2179 crores, compared to INR 2005 crores, a growth of 9%.
- Operating EBITDA: Increased by 13% to INR 649 crores from INR 576 crores.
- Profit after Tax: Registered a 17% growth to INR 410 crores versus INR 351 crores in H1 FY25.
Segment Performance
A breakdown of sales performance for Q2 FY26 compared to Q2 FY25:
- Domestic Formulations: INR 644 crores, up 9% from INR 588 crores.
- International Formulations: INR 441 crores, a 7% increase from INR 413 crores.
- Total Revenue: INR 1085 crores, an 8% rise from INR 1001 crores.
Key Business Highlights
- The domestic formulations business recorded revenue of INR 644 crores versus INR 588 crores (YoY growth of 9%).
- International business revenue grew by 7% to INR 441 crores versus INR 413 crores.
- Operating EBITDA grew by 12% to INR 319 crores versus INR 285 crores.
CEO’s Perspective
Mr. Nikhil Chopra, CEO, stated, “JB’s domestic business continued to outperform the market, with all major brands delivering robust growth. Our focus on driving steady volume growth across key brands – including recently acquired portfolios – continues to yield good results. On the international front, momentum in our CDMO business has returned, supported by a solid order book…”
Source: BSE
